about
The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism.Status quo of hybrid coronary revascularization for multi-vessel coronary artery diseaseTreatment pattern of contemporary dual antiplatelet therapies after acute coronary syndrome: a Swedish nationwide population-based cohort study.Delayed targeting of CD39 to activated platelet GPIIb/IIIa via a single-chain antibody: breaking the link between antithrombotic potency and bleeding?Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy.Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts.Platelet function and inhibition in ischemic heart disease.Influence of platelet reactivity on clinical outcome of patients with stable coronary artery disease.Platelet biology and receptor pathways.A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.Antiplatelet and anticoagulant strategies in acute coronary syndrome: where we are in 2013.A new paradigm shift in antithrombotic therapy.Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy.P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer.Study of the forced degradation behavior of prasugrel hydrochloride by liquid chromatography with mass spectrometry and liquid chromatography with NMR detection and prediction of the toxicity of the characterized degradation products.Will the epidemic of metabolic syndrome raise the prevalence of antiplatelet drug resistance?Epidemiology of CYP3A4-mediated clopidogrel drug-drug interactions and their clinical consequences.Eversion endarterectomy under full prasugrel treatment.The Platelet Lifeline to Cancer: Challenges and Opportunities.How to test the effect of aspirin and clopidogrel in patients on dual antiplatelet therapy?Effects of sarpogrelate, eicosapentaenoic acid and pitavastatin on arterioslcerosis obliterans-related biomarkers in patients with type 2 diabetes (SAREPITASO study)
P2860
Q34510681-8F14338A-DEC5-409D-B5BE-41645E706767Q35116587-55F5DA7F-AE75-4D05-A1F2-3E9ED15F3DA5Q36762574-6126C39C-4FFF-41A1-A4BF-C01839690D42Q36779378-1240F246-A213-4707-9583-0D9B47636DAEQ36976793-C5E7420F-E862-47DC-9100-9E88DEEAFC93Q37277256-2CE85409-50D1-42FC-801E-015964BA2ADAQ38007894-6CB27D46-4AA1-4EAE-85A0-4B9572C3B1EBQ38071262-9E25C07E-8C52-4BFE-98A9-2C116EC505BAQ38073155-733BBA0B-8EB7-49F7-AEFA-034984C73D61Q38098889-7CD1F89D-7621-445B-BF7F-427DC5B4B4F7Q38106501-416DA7C7-515D-475C-AAB8-6BFF48D348FBQ38155157-BAED0BBF-8A16-4790-BBAB-172A674E9E02Q38681468-3D36763F-2580-45AC-B0B0-0044A482B275Q39169265-F92700C7-E441-4E2C-82C3-AD91D2544ADAQ40793854-398BAB52-257E-45D8-86C2-9D18B63AC6A8Q41910620-221F2373-9303-48B2-8632-F063E70C191BQ46320953-17F0E95C-BDF7-4417-8904-22CD84BC50D2Q47098428-BA8CF548-1BFE-4D37-866E-372C9D21819DQ52719266-E8542AFF-3991-45A8-9CCB-0158992FA926Q53837582-32D79268-48EE-40E8-9B41-8D02027A7380Q57074152-5B9E7A9B-AD63-4DF0-A282-BEC3F8D7D8DB
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
P2Y12 platelet inhibition in clinical practice.
@en
P2Y12 platelet inhibition in clinical practice.
@nl
type
label
P2Y12 platelet inhibition in clinical practice.
@en
P2Y12 platelet inhibition in clinical practice.
@nl
prefLabel
P2Y12 platelet inhibition in clinical practice.
@en
P2Y12 platelet inhibition in clinical practice.
@nl
P2093
P2860
P921
P1476
P2Y12 platelet inhibition in clinical practice.
@en
P2093
Peter Damman
Robbert J de Winter
Stefan K James
Wichert J Kuijt
P2860
P2888
P304
P356
10.1007/S11239-011-0667-5
P577
2012-02-01T00:00:00Z